On this basis, clinical trials are currently ongoing to test miransertib, ipatasertib, uprosertib, BAY1125976, AZD5363, ARQ 751, and MSC2363318A as Akt inhibitors in several types of cancers, including OC [152,153,154]. The gene discussed is AKT1; the disease is cancer.